Valence8 US LP Portfolio
Auto-discovered active 13F filer.
SEC 13F CIK: 0001943819
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q3 2024 · 56 positions · Total reported value $238.35M · Top-10 concentration 94.2% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 6.7% · 0 new · 0 cut · 1 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): +0.4% · vs SPY -1.7% · Prev Value $300.49M — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): +0.9% · vs SPY -1.3% · Latest Value $282.95M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q3 2024 13F filing, Valence8 US LP disclosed 56 equity positions with a combined reported value of $238.35M. The filing implies a focused portfolio: its ten largest positions account for 94.2% of reported value. HoldingsHub classifies the profile as Small / Focused / Buy & Hold.
The largest disclosed positions as of Q3 2024 were QUAL ($60.51M), QQQ ($43.02M), IQLT ($42.58M). By sector, the heaviest allocations are Health Care 6.6%, Other 93.4%. Versus the prior quarter, allocation shifted toward Health Care (+6.6pp) and away from Other (-6.6pp).
Versus the prior quarter, Valence8 US LP opened 0 new positions, trimmed 0 and fully exited 1, a turnover rate of 6.7% of positions. The portfolio's overlap with the prior quarter was 16% of names.
The largest new positions opened in Q3 2024 were AZN ($4.99M), JAZZ ($999.24K), BMY ($920.20K).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q3 2024)
- AZN ASTRAZENECA PLC · $4.99M
- JAZZ JAZZ PHARMACEUTICALS PLC · $999.24K
- BMY BRISTOL-MYERS SQUIBB CO · $920.20K
- ASND ASCENDIS PHARMA A/S · $684.59K
- AMGN AMGEN INC · $644.42K
- CRSP CRISPR THERAPEUTICS AG · $615.44K
- INDV INDIVIOR PHARMACEUTICALS INC · $564.19K
- LLY ELI LILLY & CO · $560.80K
Fully Exited (vs previous quarter)
No tracked position was fully exited this quarter.
Insider Transactions (Form 4)
Latest Valence8 US LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Valence8 US LP is an SEC-registered 13F filer based in Cambridge, MA, United States. As of Q2 2026 it reported 15 US equity positions with a combined value of $300.49M. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- Headquarters: CAMBRIDGE, MA, United States
- SEC registration: 801-122837 (status: Approved), registered 2021-12-09
- Regulatory AUM (Form ADV): $1.87B as of 2026-03-20
- Client mix (by RAUM): pension and profit-sharing plans 100%, pooled investment vehicles 0%
- Manages 8 private funds, of which 4 hedge funds
Portfolio Structure
- 15 positions · $300.49M reported value (Q2 2026)
- Top 10 holdings = 92.6% of reported value
- Largest position: QUAL (ISHARES MSCI USA QUALITYFACTOR ETF) at 30.1%
- Average position size: $20.03M
Quarterly Activity
- Q2 2026: 1 new, 6 added, 6 reduced
- 2 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
337.47K | $60.51M | 25.39% | Add | |
| 2 |
|
88.15K | $43.02M | 18.05% | Add | |
| 3 |
|
1.03M | $42.58M | 17.86% | Add | |
| 4 |
|
399.19K | $22.97M | 9.63% | Hold | |
| 5 |
|
96.63K | $16.87M | 7.08% | Reduce | |
| 6 |
|
165.27K | $13.72M | 5.75% | Reduce | |
| 7 |
|
209.34K | $7.83M | 3.29% | Reduce | |
| 8 |
|
108.63K | $7.77M | 3.26% | Hold | |
| 9 |
|
64.00K | $4.99M | 2.09% | New | |
| 10 |
|
51.94K | $4.20M | 1.76% | Reduce | |
| 11 |
|
8.97K | $999.24K | 0.42% | New | |
| 12 |
|
17.79K | $920.20K | 0.39% | New | |
| 13 |
|
4.58K | $684.59K | 0.29% | New | |
| 14 |
|
2.00K | $644.42K | 0.27% | New | |
| 15 |
|
13.10K | $615.44K | 0.26% | New | |
| 16 |
|
57.29K | $564.19K | 0.24% | New | |
| 17 |
|
633 | $560.80K | 0.23% | New | |
| 18 |
|
953 | $516.60K | 0.22% | New | |
| 19 |
|
9.71K | $490.06K | 0.21% | New | |
| 20 |
|
6.60K | $481.80K | 0.20% | New | |
| 21 |
|
8.03K | $466.01K | 0.20% | New | |
| 22 |
|
3.90K | $464.37K | 0.20% | New | |
| 23 |
|
4.12K | $420.96K | 0.18% | New | |
| 24 |
|
14.10K | $414.96K | 0.17% | New | |
| 25 |
|
13.10K | $377.80K | 0.16% | New | |
| 26 |
|
26.20K | $343.61K | 0.14% | New | |
| 27 |
|
6.68K | $341.55K | 0.14% | New | |
| 28 |
|
13.19K | $310.05K | 0.13% | New | |
| 29 |
|
5.24K | $307.80K | 0.13% | New | |
| 30 |
|
13.10K | $298.02K | 0.12% | New | |
| 31 |
|
2.47K | $282.02K | 0.12% | New | |
| 32 |
|
4.10K | $274.00K | 0.12% | New | |
| 33 |
|
13.02K | $267.56K | 0.11% | New | |
| 34 |
|
33.65K | $252.04K | 0.11% | New | |
| 35 |
|
2.62K | $242.16K | 0.10% | New | |
| 36 |
|
4.24K | $235.59K | 0.10% | New | |
| 37 |
|
6.50K | $220.94K | 0.09% | New | |
| 38 |
|
19.94K | $206.57K | 0.09% | New | |
| 39 |
|
26.20K | $185.50K | 0.08% | New | |
| 40 |
|
20.30K | $172.55K | 0.07% | New | |
| 41 |
|
21.60K | $149.88K | 0.06% | New | |
| 42 |
|
23.50K | $144.29K | 0.06% | New | |
| 43 |
|
46.92K | $128.10K | 0.05% | New | |
| 44 |
|
13.10K | $123.01K | 0.05% | New | |
| 45 |
|
15.73K | $109.62K | 0.05% | New | |
| 46 |
|
2.30K | $104.49K | 0.04% | New | |
| 47 |
|
34.38K | $103.47K | 0.04% | New | |
| 48 |
|
13.10K | $99.56K | 0.04% | New | |
| 49 |
|
17.50K | $71.03K | 0.03% | New | |
| 50 |
|
14.71K | $68.54K | 0.03% | New | |
FAQ
What did Valence8 US LP buy in 2024-Q3?
In its 2024-Q3 13F filing, Valence8 US LP reported 56 equity positions worth $238.35M in aggregate; its largest disclosed positions were QUAL ($60.51M), QQQ ($43.02M), IQLT ($42.58M).
How large is Valence8 US LP's portfolio?
Valence8 US LP reported $238.35M of long equity holdings across 56 positions as of 2024-Q3. Top-10 holdings account for 94.2% of reported value.
What is Valence8 US LP's investment style?
HoldingsHub classifies the portfolio as Small / Focused / Buy & Hold, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.